



شبكة المعلومات الجامعية

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ



شبكة المعلومات الجامعية
@ ASUNET



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الالكتروني والميكرو فيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأفلام قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأفلام بعيدا عن الغبار

في درجة حرارة من ١٥-٢٥ مئوية ورطوبة نسبية من ٢٠-٤٠%

To be Kept away from Dust in Dry Cool place of
15-25- c and relative humidity 20-40%

بعض الوثائق الأصلية تالفة

بالرسالة صفحات لم ترد بالاصل

٢٥ ١١
Cup

SERUM MATRIX METALLOPROTEINASE-9 AND TISSUE INHIBITOR OF METALLOPROTEINASE-1 IN PATIENTS WITH CHRONIC LIVER DISEASES

Thesis

*Submitted in partial fulfillment of
M.D. degree in Clinical and Chemical Pathology*

By

Mennatalla Samir El-Tahawy
M.B.B. Ch., M. Sc.



Supervised By

PROD. DR. AMAL EL-MAHDY
MOHAMED SHAFAE

*Prof. Dr. of Clinical Pathology
Benha Faculty of Medicine
Benha University*

PROF. DR. AMANY HELMY
LASHEEN

*Prof. Dr. of Hepatology, Gastroenterology
and Infectious Diseases
Benha Faculty of Medicine
Benha University*

ASS. PROF. DR. MOHAMED
MOHAMED EL-SHAFAE

*Ass. Prof. of clinical pathology
Benha Faculty of Medicine
Benha University*

ASS. PROF. DR. AZZA AHMED
ABO SENNA

*Ass. Prof. of Clinical Pathology
Benha faculty of Medicine
Benha University*

*Benha Faculty of Medicine
Benha University
2005*



(يَرْفَعُ اللَّهُ الَّذِينَ آمَنُوا مِنْكُمْ
وَالَّذِينَ أُوتُوا الْعِلْمَ دَرَجَاتٍ)

صدق الله العظيم

(المجادلة: من الآية ١١)

CONTENTS

Title	Page
Introduction.....	1
Aim of the work.....	3
Review of Literature	
<i>Chapter one : Chronic liver diseases</i>	4
<i>Chapter two: Hepatic fibrosis and cirrhosis</i>	37
<i>Chapter three : Matrix metalloproteinases and their inhibitors</i>	77
Subjects and Methods	98
Statistical Analysis	115
Results	120
Discussion	156
Summary, Conclusions and recommendation.....	170
References	174
Master Sheets	
Arabic Summary	

LIST OF TABLES

Table (1)	Classification of chronic hepatitis	6
Table (2)	Comparison of two common types of chronic hepatitis B viral infection.	12
Table (3)	Summary of interpretation of serologic tests for hepatitis C viral infection	25
Table (4)	Causes of fibrosis and cirrhosis	39
Table (5)	Collagen types	45
Table (6)	HAI for numerical scoring of liver biopsy specimens	65
Table (7)	Desmet's modification of Knodell scoring system	66
Table (8)	Reagents provided for MMP-9 determination	104
Table (9)	Reagents provided for TIMP-1 determination	110
Table (10)	Dilution of hTIMP-1 Standard	111
Table (11)	Comparison of liver function tests between the studied groups	121
Table (12)	Comparison of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio between studied groups.	123
Table (13)	Comparison of MMP-9, TIMP-1 and MMP-9/ TIMP-1 ratio between HCV Ab +ve and -ve cases.	126
Table (14)	Comparison of MMP-9, TIMP-1 and MMP-9/ TIMP-1 ratio between HBsAg +ve and -ve cases.	127
Table (15)	Comparison of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio between Bilharzial Ab +ve and -ve cases..	128
Table (16)	Distribution of cases according to pathological diagnostic results of 45 liver biopsy samples.	129
Table (17)	Comparison of different stages of liver fibrosis diagnosed by liver biopsy as regard liver function tests, MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio.	130

Table (18)	Comparison of different grades of inflammation diagnosed by liver biopsy as regard liver function tests, MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio.	132
Table (19)	Correlation coefficient (r) between MMP-9 and liver functions tests.	134
Table (20)	Correlation coefficient (r) between TIMP-1 and liver function tests.	135
Table (21)	Sensitivity (SN), specificity (SP), positive predictive value (P^+), negative predictive value (P^-) and efficiency (EFF) of TIMP-1 in diagnosis of stage of fibrosis (F0, F1, F ₂ vs, F3, F4)	138
Table (22)	Sensitivity (SN), specificity (SP), positive predictive value (P^+), negative predictive value (P^-) and efficiency (EFF) of TIMP-1 in diagnosis of grade of inflammation (A0, A1, vs A2)	139
Table (23)	Sensitivity (SN), specificity (SP), positive predictive value (P^+), negative predictive value (P^-) and efficiency (EFF) of MMP-9 in diagnosis of stage of fibrosis of (F0, F1, F2 vs F3, F4).	140
Table (24)	Sensitivity (SN), specificity (SP), positive predictive value (P^+), negative predictive value and efficiency (EFF) of MMP-9 in diagnosis of grade of inflammation (A0, A1 vs A2).	141
Table (25)	Sensitivity (SN), specificity (SP), positive predictive value (P^+), negative predictive value and efficiency (EFF) of MMP-9/TIMP-1 ratio in diagnosis of stage of fibrosis of (F0, F1, F2 vs F3, F4).	142
Table (26)	Sensitivity (SN), specificity (SP), positive predictive value (P^+), negative predictive value and efficiency (EFF) of	143

	MMP-9/TIMP-1 ratio in diagnosis of grade of inflammation (A0, A1 vs A2).	
Table (27)	Stepwise multiregression analysis in diagnosis of stage of fibrosis.	146
Table (28)	Data of patients group	
Table (29)	Data of controls group	

LIST OF FIGURES

Fig. (1)	Sinusoidal events during fibrosing liver injury	50
Fig. (2)	Phenotypic features of hepatic stellate cell activation during liver injury and resolution	59
Fig. (3)	Matrix metalloproteinase domain structure.	80
Fig. (4)	Domain arrangement of vertebrate maxitrins	80
Fig. (5)	Dilution of MMP-9 standard	106
Fig. (6)	Standard curve for MMP-9	108
Fig. (7)	Standard curve for TIMP-1	114
Fig. (8)	Comparison between controls and patients groups as regards mean values of ALT, AST, ALP and GGT	122
Fig. (9)	Comparison between controls and patients groups as regard mean values of Total and Direct Bilirubin	122
Fig. (10)	Scatterdiagram showing distribution of studied groups as regard MMP-9.	124
Fig. (11)	Scatterdiagram showing distribution of studied groups as regards TIMP-1	124
Fig. (12)	Scatterdiagram showing distribution of studied groups as regard MMP-9/TIMP-1 ratio.	125
Fig. (13)	Scatterdiagram showing distribution of cases (stages of fibrosis) as regards TIMP-1	131
Fig. (14)	Scatterdiagram showing distribution of cases (stages of fibrosis) as regards MMP-9	131
Fig. (15)	Scatterdiagram showing distribution of cases (grades of inflammation) as regards TIMP-1	133
Fig. (16)	Scatterdiagram showing distribution of cases (grades of inflammation) as regards MMP-9	133
Fig. (17)	Linear regression analysis showing correlation between TIMP-1 and GGT among patient group	136
Fig. (18)	Linear regression analysis showing correlation between TIMP-1 and AST among patient group	137
Fig. (19)	ROC curve analysis showing the diagnostic performance of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio for discriminating patients with extensive from those with mild fibrosis	144
Fig. (20)	ROC curve analysis showing the diagnostic performance of MMP-9, TIMP-1 and MMP-9/TIMP-1 for discriminating patients with extensive from those with mild inflammation	145

Histopathological examination of liver biopsy using Metavir score for some patient		
Fig. (21)	Normal liver liver biopsy (H&E, X 200)	147
Fig. (22)	Normal liver biopsy (Masson Trichrome stain, X 200)	147
Fig. (23)	Chronic interface hepatitis (HCV); METAVIR: A1, F1. (H&E, X 200)	148
Fig. (24)	Mild fibrosis. METAVIR: F1. (Masson Trichrome stain, X200)	148
Fig. (25)	Moderate portal fibrosis METAVIR: F2 (H & E, X 200).	149
Fig. (26)	Moderate portal fibrosis METAVIR: F2 (Masson Trichrome, X 200).	149
Fig. (27)	Chronic hepatitis C with Schistosomiasis METAVIR; A2, F2. (H & E, X 200).	150
Fig. (28)	Chronic hepatitis with moderate fibrosis. METAVIR: F2. (Masson Trichrome stain, X200)	150
Fig. (29)	Chronic hepatitis C with precirrhotic changes, and bilharzial hepatic fibrosis METAVIR: A2, F3. (H & E, X 100).	151
Fig. (30)	Higher power view of the liver biopsy shown in figure (29) (H&E, X 200).	151
Fig. (31)	Post hepatitis C-cirrhosis METAVIR: A2, F 4 (cirrhosis). (H & E, X 100).	152
Fig. (32)	Higher power view of the liver biopsy shown in Fig. (31) (H & E, X 200)	152
Fig. (33)	Chronic interface hepatitis (mixed HCV and HBV) with cirrhotic architecture METAVIR: A2, F4. (H&E, X 100)	153
Fig. (34)	Higher power view of the liver biopsy shown in figure (33). (H&E, X 200).	153
Fig. (35)	Masson Trichrome staining of the liver biopsy shown in figures (31) and (33) (X 200).	154
Fig. (36)	Orcein staining shows liver cells containing HBsAg. (X 200).	154
Fig. (37)	Orcein staining showing liver cells containing HBsAg (X 200).	155

LIST OF ABBREVIATIONS

Alb	:	Albumin
ALP	:	Alkaline phosphatase
ALT	:	Alanine aminotransferase
ANA	:	Antinuclear antibodies
Anti- HBs	:	Anti hepatitis B surface antigen
Anti-HBc	:	Anti hepatitis B core antigen
Anti-HCV	:	Anti hepatitis C virus
Anti-HDV	:	Anti hepatitis Delta virus
APO A1	:	Apolipoprotein A-1
AST	:	Asparate aminotransferase
AT	:	Acti test
AUC	:	Area under curve
α 2-M	:	Alpha 2 macroglobulin
BCG	:	Bronmocrsol green
bFGF	:	Basic fibroblast growth factor
Bp	:	Base pair
CTGF	:	Connective tissue growth factor
DB	:	Direct bilirubin
DNA	:	Deoxy ribonucleic acid
ECM	:	Extracellular matrix
EFF	:	Efficacy
EGF	:	Epidermal growth factor
EIA	:	Enzyme linked immunoassay
ELISA	:	Enzyme linked immunosorbant assay
FN	:	False negative
FP	:	False positive
FT	:	Fibrotest

γ GT	:	Gamma glutamyl transpeptidase
h	:	Kruskall wallis test
HA	:	Hyaluronic acid
HAI	:	Histological activity index
HBcAg	:	Hepatitis B core antigen
HBeAg	:	Hepatitis B envelop antigen
HBs Ag	:	Hepatitis B surface antigen
HBV	:	Hepatitis B virus
HCC	:	Hepatocellular carcinoma
HCV	:	Hepatitis C virus
HCV Ab	:	Hepatitis C viral antibody
HCVAg	:	Hepatitis C viral antigen
HDAg	:	Hepatitis D antigen
HDV	:	Hepatitis delta virus
HEV	:	Hepatitis E virus
HGF	:	Hepatocytes growth factor
HGV	:	Hepatitis G virus
HIV	:	Human immunodeficiency virus
HRECs	:	Human retinal microvascular endothelial cells
HRP	:	Human radish peroxidase
HSCs	:	Hepatic stellate cells
hTIMP-1	:	Human tissue inhibitor of metalloproteinase-1
HVR	:	Hypervariable region
ICAM-1	:	Intracellular adhesion molecule -1
IgG	:	Immunoglobulin G
IgM	:	Immunoglobulin M
IHA	:	Immune haemagglutination
IL	:	Interleukin